CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$2.09-3.24%
Price as of Jul 20, 2026
CVKD growth
Cadrenal Therapeutics, Inc. Common Stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- +7.9%
- EBIT
- +8.3%
- EPS
- +39.2%
- Free cash flow
- -7.6%
- Operating cash flow
- -7.7%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +51.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -24.2%
- EBIT
- -22.8%
- Net income
- -24.3%
- EPS
- +23.9%
- Free cash flow
- -71.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.